Investor's Business Daily : declared in Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst

RELATED:Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis ClimbsAstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: LeerinkTesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst The sell-off Tuesday on Tesaro (TSRO) stock was overdone, an analyst argued Wednesday, after rival AstraZeneca (AZN) revealed strong ovarian-cancer trial data — prompting facebook/" target="_blank">shares of Tesaro and Clovis Oncology (CLVS) to diverge. In a separate trial, Tesaro found its drug, niraparib, could delay reoccurrence by 21 months in a similar patient population. AstraZeneca, Clovis and Tesaro are working on a class of drugs called PARP inhibitors. On Tuesday, AstraZeneca unveiled data showing that its FDA-approved Lynparza was able to delay the reoccurrence of ovarian cancer by 30.2 months.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

While Lynparza's study only evaluated its use in BRCA mutation patients, niraparib worked successfully in ovarian cancer patients without BRCA mutation. The FDA approved Rubraca in December for use in ovarian cancer patients who have seen their disease return following two prior platinum-based chemotherapies. Regardless, until there's a cure for ovarian cancer, Lynparza, Rubraca, and niraparib could all play important roles in helping patients live longer, and that means they could all be a commercial success. Getting crowdedDespite its limited approval, Lynparza sales exited December at an annualized $240 million clip, and given that most ovarian cancer patients relapse, the potential market opportunity for Lynparza, and its PARP-inhibiting competitors, is big. However, it also poses the greatest pill burden, because it's taken three times daily, rather than twice-daily like Lynparza and Rubraca.



collected by :Lucy William

To follow all the new news about Disease !!! All you need to know about all kinds of diseases